Certara is a global provider of biosimulation science, technology, and consulting services that help biopharmaceutical and biotech companies optimize drug development through Model-Informed Drug Development (MIDD). The company's integrated offerings include mechanistic and empirical simulation platforms (Simcyp and Phoenix), scientific informatics and drug discovery tools, regulatory and clinical data management software (Pinnacle 21, CoAuthor, GlobalSubmit), and scientist-led consulting services spanning quantitative systems pharmacology, pharmacometrics, clinical pharmacology, and regulatory strategy. Certara serves over 2,600 customers across biopharmaceutical companies, contract research organizations, academic institutions, and regulatory agencies in 70 countries, generating revenue primarily through recurring software subscriptions and project-based consulting services that help reduce drug development timelines, costs, and approval risks.